A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854
administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.